CERo Therapeutics Holdings (CERO) Price & Analysis

Compare

491 Followers

CERO Stock Chart & Stats

$0.07

-$1.53(-29.25%)

At close: Jan 08 4:00 PM EST

$0.07

-$1.53(-29.25%)

Day’s Range― - ―

52-Week Range$0.05 - $508.75

Previous Close$3.66

Volume998.67K

Average Volume (3M)241.38K

Market Cap

$121.14K

Enterprise ValueN/A

Total Cash (Recent Filing)$2.02M

Total Debt (Recent Filing)$931.02K

Price to Earnings (P/E)―

Beta-0.65

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-38.99

Shares Outstanding1,205,402

10 Day Avg. Volume494,514

30 Day Avg. Volume241,383

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)-76.51

Price to Sales (P/S)0.00

P/FCF Ratio-25.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$0.10

Price Target Upside42.86% Upside

Rating ConsensusHold

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentCERo's CER-1236 modified T cells employ the extracellular domain of TIM-4, potentially mitigating cytokine release syndrome and neurotoxicity seen in traditional CAR-T therapies.

Safety ProfileNo safety issues reported so far, with one patient in the first cohort cleared for dose intensification, indicating a positive safety profile.

Unique Therapeutic ApproachThe unique approach of using TIM-4 receptor in CER-1236 structure is seen as a key differentiator from other CAR-T therapies.

Bears Say

Price Target ReductionThe net effect of factoring in dilution and associated changes reduces the price target to $15, from $60.

Rating DowngradeCERO shares were downgraded to Hold from Buy following the announcement that they were to be delisted.

Stock DelistingThe Hold rating is maintained based on the delisting of CERO shares from NASDAQ.

CERo Therapeutics Holdings News

Cero Therapeutics downgraded to Hold from Buy at D. Boral Capital

D. Boral Capital analyst Jason Kolbert downgraded Cero Therapeutics (CERO) to Hold from Buy with no price target...

4d ago

CERO

Cero Therapeutics initiates second cohort in Phase 1 trial of CER-1236

CERo Therapeutics (CERO) announces the initiation of the second cohort of its Phase 1 CER-1236 clinical trial focused...

17d ago

CERO

Cero Therapeutics to present data on CER-1236 at SITC conference

CERo Therapeutics (CERO) will be presenting data on its lead compound CER-1236 at the Society for Immunotherapy of...

18d ago

CERO

Cero Therapeutics announces listing on OTC Markets

CERo Therapeutics (CERO) announces its shares continue to be listed on the public markets under the ticker symbol...

19d ago

CERO

Cero Therapeutics downgraded to Hold from Buy at Maxim

Maxim analyst Jason McCarthy downgraded Cero Therapeutics (CERO) to Hold from Buy. Published first on TheFly – the...

19d ago

CERO

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Earnings reports dominate the stock market headlines worth checking out on Thursday. ...

23d ago

Why Is CERo Therapeutics Stock Down 80% Today?

CERo Therapeutics stock fell hard on Thursday following a delisting notice. ...

23d ago

CERO

Cero Therapeutics discloses Nasdaq Panel listing determination

CERo Therapeutics (CERO) “announced the receipt of the determination of the Nasdaq Hearings Panel to deny the Company’s...

24d ago

CERO

CERo Therapeutics Delays Quarterly Report Filing

CERo Therapeutics Holdings ( ($CERO) ) has released a notification of late filing. CERo Therapeutics Holdings, Inc. has...

5d ago

CERO

CERo Therapeutics Faces Nasdaq Delisting Suspension

An announcement from CERo Therapeutics Holdings ( ($CERO) ) is now available. On October 29, 2025, CERo Therapeutics...

23d ago

CERO

Cero Therapeutics’ Innovative AML Treatment Study: A Potential Game-Changer?

Cero Therapeutics Holdings, Inc. (($CERO)) announced an update on their ongoing clinical study. Study Overview: Cero Therapeutics Holdings,...

26d ago

CERO

Cero announces third dose for patients in Phase 1 trial of CER-1236

CERo Therapeutics (CERO) announced that investigators have been authorized under the study protocol to administer a third infusion...

1M ago

CERO

CERo Therapeutics Expands Securities Purchase Agreement

The latest update is out from CERo Therapeutics Holdings ( ($CERO) ). On October 16, 2025, CERo Therapeutics...

1M ago

CERO

CERo Therapeutics Enters Securities Purchase Agreement

The latest announcement is out from CERo Therapeutics Holdings ( ($CERO) ). CERo Therapeutics Holdings, Inc., a Delaware...

1M ago

CERO

CERO FAQ

What was CERo Therapeutics Holdings’s price range in the past 12 months?

CERo Therapeutics Holdings lowest stock price was $0.05 and its highest was $508.75 in the past 12 months.

What is CERo Therapeutics Holdings’s market cap?

CERo Therapeutics Holdings’s market cap is $121.14K.

When is CERo Therapeutics Holdings’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were CERo Therapeutics Holdings’s earnings last quarter?

Currently, no data Available

Is CERo Therapeutics Holdings overvalued?

According to Wall Street analysts CERo Therapeutics Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CERo Therapeutics Holdings pay dividends?

CERo Therapeutics Holdings does not currently pay dividends.

What is CERo Therapeutics Holdings’s EPS estimate?

CERo Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CERo Therapeutics Holdings have?

CERo Therapeutics Holdings has 1,205,402 shares outstanding.

What happened to CERo Therapeutics Holdings’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of CERo Therapeutics Holdings?

Among the largest hedge funds holding CERo Therapeutics Holdings’s share is Saba Capital Management. It holds CERo Therapeutics Holdings’s shares valued at 0.

Company Description

CERo Therapeutics Holdings

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

CERO Stock 12 Month Forecast

Average Price Target

$0.10

▲(42.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"356":"$356","-1":"-$1","88.25":"$88.3","177.5":"$177.5","266.75":"$266.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,88.25,177.5,266.75,356],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.07,0.07230769230769231,0.07461538461538463,0.07692307692307693,0.07923076923076924,0.08153846153846155,0.08384615384615385,0.08615384615384616,0.08846153846153847,0.09076923076923077,0.09307692307692308,0.09538461538461539,0.09769230769230769,{"y":0.1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.07,0.07230769230769231,0.07461538461538463,0.07692307692307693,0.07923076923076924,0.08153846153846155,0.08384615384615385,0.08615384615384616,0.08846153846153847,0.09076923076923077,0.09307692307692308,0.09538461538461539,0.09769230769230769,{"y":0.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.07,0.07230769230769231,0.07461538461538463,0.07692307692307693,0.07923076923076924,0.08153846153846155,0.08384615384615385,0.08615384615384616,0.08846153846153847,0.09076923076923077,0.09307692307692308,0.09538461538461539,0.09769230769230769,{"y":0.1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":254.4,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":205.2,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":166.2,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":355.2,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":120,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":42.8,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.4,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.4,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >